NEW OPPORTUNITIES FOR THE TREATMENT OF UNCONTROLLED ASTHMA IN RUSSIA



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Bronchial asthma (BA) is one of the most socially significant diseases of the respiratory system. The control over the symptoms of BA is achieved less than in 50% of cases even in highly developed countries. The reasons for the lack of control are heterogeneous. One of the most important reasons for the lack of control over symptoms BA in Russia is the unavailability of highly effective drugs for socially unprotected layers of the population. The solution of this problem could be the creation of Russian analogs for asthma treatment. A new Russian product - a combination of topical corticosteroids and DBA (fluticasone/salmeterol) - Suticase-native is going to appear on the Russian market. A study to assess the efficacy and safety of the new product was carried out on the base of three Russian scientific centers. This trail compared a new drug Suticase-nativ (salmeterol 50 mcg plus fluticasone propionate 250 mcg/dose), powder for inhalation (produced by «Nativ» - company, Russia), with its famous counterpart - a Seretide accuhaler diskus (salmeterol 50 mcg plus fluticasone propionate 250 mcg/ dose), powder for inhalation dosed, production Glaxo Operates UK Ltd, in patients with bronchial asthma. The results of the study showed high efficiency and safety of Suticase-Nativ, comparable to Seretide.

Full Text

Restricted Access

About the authors

N I Ilina

Institute of Immunology

Moscow, Russia

N V Shartanova

Institute of Immunology

Moscow, Russia

E A Latysheva

Institute of Immunology

Email: ealat@mail.ru
Moscow, Russia

M A Denisov

Diagnostic center of Vladimir

References

  1. Plusa T Modem threats and burden of respiratory system diseases in Poland. Pol. Merkur. Lekarski. 2013, v. 35, р. 287291.
  2. Agrawal S., Pearce N., Ebrahim S. Prevalence and risk factors for self-reported asthma in an adult Indian population: a cross-sectional survey. Int. J. Tuberc. Lung. Dis. 2011, v. 17, р. 275-282.
  3. Dejsomritrutai W, Nana A., Chierakul N. et al. Prevalence of bronchial hyperresponsiveness and asthma in the adult population in Thailand. Chest. 2006, v. 129, р. 602-609.
  4. Fukutomi Y., Nakamura H., Kobayashi F. et al. Nationwide cross-sectional population-based study on the prevalence of asthma and asthma symptoms among Japanese adults. Int Arch. Allergy Immunol. 2010, v. 153, р. 280-287.
  5. Jindal S.K., Aggarwal A.N., Gupta D. et al. Indian study on epidemiology of asthma, respiratory symptoms and chronic bronchitis in adults (InSeARCH) Int. J. Tuberc. Lung. Dis. 2012, v. 16, р. 1270-1277.
  6. Lu Y, Feng L., Lim L., Ng T.P. Asthma, life events and psychiatric disorders: a population-based study. Soc. Psychiatry Psychiatr. Epidemiol. 2013, v. 48, р. 1273-1282.
  7. Mahboub B.H., Al-Hammadi S., Rafique M. et al. Population prevalence of asthma and its determinants based on European Community Respiratory Health Survey in the United Arab Emirates. BMC Pulm. Med. 2012, v. 12, р. 4.
  8. Laren D. Tan, Andrew L. Chan, Timothy E. Albertson New combination treatments in the management of asthma: focus on fluticasone/vilanterol. J. Asthma Allergy. 2014, v. 7, р. 77-83.
  9. Caminati M., Magnoni M.S., Rizzi A. et al. Asthma management among different specialists: results from a national Italian survey Eur. Ann. Allergy Clin. Immunol. 2014, v. 46, р. 74-82.
  10. Albertson T.E., Schivo M., Gidwani N. et al. Pharmacotherapy of critical asthma syndrome: current and emerging therapies. Clin. Rev. Allergy Immunol. 2013, v. 2, р. 42-48.
  11. Raissy H.H., Kelly H.W., Harkins M., Szefler S.J. Inhaled corticosteroids in lung diseases. Am. J. Respir. Crit. Care Med. 2013, v. 187, р. 798-803.
  12. Черняк Б.А., Воржева И.И. Агонисты Р2-адренергических рецепторов в терапии бронхиальной астмы: вопросы эффективности и безопасности. Consilium medicum. 2006, № 10, с. 62-68.
  13. Kramer J.M. Balancing the benefits and risks of inhaled long-acting beta-agonists - the influence of values. N. Engl. J. Med. 2009, v. 360, р. 1592-1595.
  14. National Institutes of Health, National Heart, Lung and Blood Institute. Global Initiative for asthma: pocket Guide for Asthma Management and Prevention. NHLBI/WHO NIH; 1998. Publication №з. 96-36558B.
  15. Ducharme F.M., Ni Chroinin M., Greenstone I., Lasserson T.J. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst. Rev. 2010, v. 14, CD005533.
  16. Murray J., Rosenthal R., Somerville L. et al. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting b2-agonists. Allergy Asthma Immunol. 2004, v. 93, р. 351-359.
  17. Strand A.M., Luckow A. Initiation of maintenance treatment of persistent asthma: salmeterol/fluticasone propionate combination treatment is more effective than inhaled steroid alone. Respir. Med. 2004, v. 98, р. 1008-1015.
  18. Nguyen W.T, Stewart C., Fisher K. et al. Maintenance asthma treatment with fluticasone/salmeterol combination via Diskus: effect on outcomes in inner-city children enrolled in Tenn Care. Allergy Asthma Proc. 2005, v. 26, р. 129-134.
  19. You-Ning L., Humphries M., Du X. et al. Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids. Int. J. Clin. Pract. 2005, v. 59, р. 754-759.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2014



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies